Beijing SL Pharmaceutical Co Ltd (002038) — Net Asset Quality Index
Beijing SL Pharmaceutical Co Ltd (002038) has a Net Asset Quality Index of 87.4% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥5.84 Billion minus total liabilities of CN¥735.46 Million yields net assets of CN¥5.10 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Read 002038 liabilities breakdown for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
Beijing SL Pharmaceutical Co Ltd Net Asset Quality Index Over Time (2001–2025)
This chart shows how Beijing SL Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 25 annual periods from 2001 to 2025. As of March 2026, the index stands at 87.4%, representing net assets of CN¥5.10 Billion against total assets of CN¥5.84 Billion CNY. For live market cap and overall valuation, see 002038 company net worth.
Annual Net Asset Quality Index for Beijing SL Pharmaceutical Co Ltd (2001–2025)
The table below presents the year-by-year Net Asset Quality Index for Beijing SL Pharmaceutical Co Ltd from 2001 to 2025, covering 25 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. Check 002038 strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 85.4% | CN¥5.19 Billion | CN¥6.07 Billion | CN¥883.49 Million | ▼ -7.9 pp |
| 2024 | 93.3% | CN¥5.58 Billion | CN¥5.98 Billion | CN¥398.37 Million | ▲ +0.8 pp |
| 2023 | 92.5% | CN¥5.81 Billion | CN¥6.28 Billion | CN¥467.72 Million | ▼ -0.7 pp |
| 2022 | 93.3% | CN¥5.48 Billion | CN¥5.88 Billion | CN¥396.60 Million | ▲ +0.8 pp |
| 2021 | 92.5% | CN¥5.33 Billion | CN¥5.76 Billion | CN¥434.23 Million | ▲ +0.1 pp |
| 2020 | 92.4% | CN¥4.98 Billion | CN¥5.39 Billion | CN¥410.09 Million | ▲ +0.1 pp |
| 2019 | 92.3% | CN¥4.82 Billion | CN¥5.22 Billion | CN¥403.76 Million | ▲ +1.7 pp |
| 2018 | 90.6% | CN¥4.52 Billion | CN¥4.99 Billion | CN¥469.73 Million | ▼ -3.2 pp |
| 2017 | 93.8% | CN¥4.30 Billion | CN¥4.59 Billion | CN¥285.67 Million | ▼ -2.5 pp |
| 2016 | 96.3% | CN¥3.93 Billion | CN¥4.08 Billion | CN¥151.19 Million | ▲ +0.2 pp |
| 2015 | 96.1% | CN¥3.61 Billion | CN¥3.76 Billion | CN¥148.40 Million | ▲ +0.2 pp |
| 2014 | 95.8% | CN¥3.18 Billion | CN¥3.32 Billion | CN¥137.92 Million | ▲ +0.4 pp |
| 2013 | 95.5% | CN¥2.59 Billion | CN¥2.71 Billion | CN¥123.09 Million | ▲ +0.2 pp |
| 2012 | 95.3% | CN¥2.11 Billion | CN¥2.22 Billion | CN¥105.17 Million | ▼ -1.8 pp |
| 2011 | 97.1% | CN¥1.69 Billion | CN¥1.74 Billion | CN¥50.52 Million | ▲ +0.1 pp |
| 2010 | 97.0% | CN¥1.21 Billion | CN¥1.25 Billion | CN¥37.22 Million | ▲ +0.6 pp |
| 2009 | 96.4% | CN¥983.06 Million | CN¥1.02 Billion | CN¥36.75 Million | ▼ -0.3 pp |
| 2008 | 96.7% | CN¥762.61 Million | CN¥788.52 Million | CN¥25.91 Million | ▲ +2.6 pp |
| 2007 | 94.1% | CN¥551.93 Million | CN¥586.63 Million | CN¥34.71 Million | ▲ +1.8 pp |
| 2006 | 92.3% | CN¥426.20 Million | CN¥461.61 Million | CN¥35.41 Million | ▼ -1.9 pp |
| 2005 | 94.2% | CN¥382.49 Million | CN¥405.91 Million | CN¥23.42 Million | ▲ +1.5 pp |
| 2004 | 92.7% | CN¥361.45 Million | CN¥389.83 Million | CN¥28.38 Million | ▲ +16.9 pp |
| 2003 | 75.8% | CN¥115.05 Million | CN¥151.83 Million | CN¥36.78 Million | ▼ -7.5 pp |
| 2002 | 83.2% | CN¥85.61 Million | CN¥102.84 Million | CN¥17.23 Million | ▼ -2.7 pp |
| 2001 | 85.9% | CN¥66.29 Million | CN¥77.13 Million | CN¥10.84 Million | — |